Saturday, June 29, 2024
Genoks, a leading Turkish genomics healthcare company, and Velsera, a global healthcare technology firm, have announced a strategic partnership to advance cancer diagnostics and treatment in Turkey and neighboring regions.
This collaboration combines Genoks' genomics expertise with Velsera's Clinical Genomics Workspace (CGW), a platform for comprehensive analysis of solid tissue, liquid tumor, and hematological cancer samples.
By integrating CGW, Genoks aims to enhance the accuracy of cancer detection and characterization through Velsera's advanced genomic analysis and data interpretation capabilities.
"They are excited to partner with Velsera in our mission to transform cancer diagnostics and treatment in Turkey and beyond."
"Together, they can make a significant impact in the fight against cancer, providing clinicians with precise insights to guide treatment decisions and improve patient outcomes."
The Clinical Genomics Workspace is designed for oncology and inherited disease specialists, including physicians and clinical laboratory professionals. It aims to remove barriers to establishing or expanding Next-Generation Sequencing (NGS) testing programs.
CGW supports molecular diagnostics experts in physician-owned laboratories, large hospitals, and reference labs globally.
Through this collaboration, Genoks seeks to strengthen its position as a leader in oncology diagnostics in Turkey, offering advanced testing solutions for precise and personalized cancer care.
Velsera's algorithms and tools will enable Genoks to provide actionable insights, helping clinicians make informed treatment decisions based on each patient's genetic profile.
This partnership represents a significant milestone in oncology, emphasizing the importance of strategic collaborations in advancing cancer research and improving patient care.
With a shared commitment to innovation and excellence, Genoks and Velsera are poised to make a lasting impact on cancer treatment in Turkey and beyond.
Source: businesswire.com
